Breast cancer vaccines for treatment and prevention

Disis, Mary L.; Cecil, Denise L.

doi:10.1007/s10549-021-06459-2

Cited by 17 publications

(14 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Neoantigen cancer vaccine can induce an immune response to a tumor-specific antigen (neoantigen) and lead to the generation and expansion of T lymphocytes recognizing tumor antigens and restrict tumor growth. Breast cancer, particularly the TNBC subtype, is immunogenic, and a variety of vaccines have been designed to boost immunity directed against the disease ( 61 ). Although several vaccines have advanced to large randomized phase II or phase III clinical trials, none of these trials using cancer vaccine as a single agent met their primary endpoint of either progression-free survival or OS.…”

Section: Immune Molecule-based Therapymentioning

confidence: 99%

Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer

Luo

Wang

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

Breast cancer is the most commonly diagnosed cancer (estimated 2.3 million new cases in 2020) and the leading cause of cancer death (estimated 685,000 deaths in 2020) in women globally. Breast cancers have been categorized into four major molecular subtypes based on the immunohistochemistry (IHC) expression of classic hormone and growth factor receptors including the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), as well as a proliferation marker Ki-67 protein expression. Triple-negative breast cancer (TNBC), a breast cancer subtype lacking ER, PR, and HER2 expression, is associated with a high metastatic potential and poor prognosis. TNBC accounts for approximately only 15%–20% of new breast cancer diagnoses; it is responsible for most breast cancer–related deaths due to the lack of targeted treatment options for this patient population, and currently, systemic chemotherapy, radiation, and surgical excision remain the major treatment modalities for these patients with TNBC. Although breast cancer patients in general do not have a robust response to the immunotherapy, a subset of TNBC has been demonstrated to have high tumor mutation burden and high tumor-infiltrating lymphocytes, resembling the features observed on melanoma or lung cancers, which can benefit from the treatment of immune checkpoint inhibitors (ICIs). Therefore, the immunogenic nature of this aggressive disease has presented an opportunity for the development of TNBC-targeting immunotherapies. The recent US Food and Drug Administration approval of atezolizumab in combination with the chemotherapeutic agent nab-paclitaxel for the treatment of PD-L1-positive unresectable, locally advanced, or metastatic TNBC has led to a new era of immunotherapy in TNBC treatment. In addition, immunotherapy becomes an active research area, both in the cancer biology field and in the oncology field. In this review, we will extend our coverage on recent discoveries in preclinical research and early results in clinical trials from immune molecule-based therapy including cytokines, monoclonal antibodies, antibody–drug conjugates, bi-specific or tri-specific antibodies, ICIs, and neoantigen cancer vaccines; oncolytic virus-based therapies and adoptive immune cell transfer–based therapies including TIL, chimeric antigen receptor-T (CAR-T), CAR-NK, CAR-M, and T-cell receptor-T. In the end, we will list a series of the challenges and opportunities in immunotherapy prospectively and reveal novel technologies such as high-throughput single-cell sequencing and CRISPR gene editing-based screening to generate new knowledges of immunotherapy.

show abstract

Section: Immune Molecule-based Therapymentioning

confidence: 99%

Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer

Luo

Wang

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…As early as 2010, the FDA approved the first autologous active immunotherapy drug and the first truly therapeutic cancer vaccine Provenge/Sipuleucel-T to treat advanced prostate cancer (PCa) [ 137 ]. This marked the entry of tumor treatment into the era of vaccine treatment, which was followed by remarkable results in tumor vaccine therapy in the field of BRCA treatment [ 136 , 138 ]. In December 2020, the SABCS conference announced a prospective, multicenter, single-blind, placebo-controlled, Phase IIb RCT on the new BRCA vaccine GP2, i.e., HER2 targeted therapy plus GP2 vaccine treatment, resulting in a five-year disease-free survival rate of 100% and a recurrence rate of 0% in patients with BRCA (NCT03014076), which means that all patients who received the vaccine treatment regimen experienced a clinical cure.…”

Section: Muc1-mediated Brca Immunotherapymentioning

confidence: 99%

Advances in MUC1-Mediated Breast Cancer Immunotherapy

Yang

Guo

et al. 2022

Biomolecules

View full text Add to dashboard Cite

Breast cancer (BRCA) is the leading cause of death from malignant tumors among women. Fortunately, however, immunotherapy has recently become a prospective BRCA treatment with encouraging achievements and mild safety profiles. Since the overexpression and aberrant glycosylation of MUC1 (human mucin) are closely associated with BRCA, it has become an ideal target for BRCA immunotherapies. In this review, the structure and function of MUC1 are briefly introduced, and the main research achievements in different kinds of MUC1-mediated BRCA immunotherapy are highlighted, from the laboratory to the clinic. Afterward, the future directions of MUC1-mediated BRCA immunotherapy are predicted, addressing, for example, urgent issues in regard to how efficient immunotherapeutic strategies can be generated.

show abstract

“…Taking into account the latter group, the HER2 oncogene is an excellent candidate for vaccine development [ 13 , 14 ]. Its role has become increasingly evident and attracted much research with a number of formulations already in clinical trials [ 15 , 16 ]. Furthermore, in order to properly expand the immune response against tumors, a vaccine must effectively target DCs, which play a critical role in inducing proper immune activation [ 10 ].…”

Section: Introductionmentioning

confidence: 99%

Exploring chitosan-shelled nanobubbles to improve HER2 + immunotherapy via dendritic cell targeting

Argenziano

Occhipinti

Scomparin

et al. 2022

Drug Deliv. and Transl. Res.

View full text Add to dashboard Cite

Immunotherapy is a valuable approach to cancer treatment as it is able to activate the immune system. However, the curative methods currently in clinical practice, including immune checkpoint inhibitors, present some limitations. Dendritic cell vaccination has been investigated as an immunotherapeutic strategy, and nanotechnology-based delivery systems have emerged as powerful tools for improving immunotherapy and vaccine development. A number of nanodelivery systems have therefore been proposed to promote cancer immunotherapy. This work aims to design a novel immunotherapy nanoplatform for the treatment of HER2 + breast cancer, and specially tailored chitosan-shelled nanobubbles (NBs) have been developed for the delivery of a DNA vaccine. The NBs have been functionalized with anti-CD1a antibodies to target dendritic cells (DCs). The NB formulations possess dimensions of approximately 300 nm and positive surface charge, and also show good physical stability up to 6 months under storage at 4 °C. In vitro characterization has confirmed that these NBs are capable of loading DNA with good encapsulation efficiency (82%). The antiCD1a-functionalized NBs are designed to target DCs, and demonstrated the ability to induce DC activation in both human and mouse cell models, and also elicited a specific immune response that was capable of slowing tumor growth in mice in vivo. These findings are the proof of concept that loading a tumor vaccine into DC-targeted chitosan nanobubbles may become an attractive nanotechnology approach for the future immunotherapeutic treatment of cancer. Graphical abstract

show abstract

Breast cancer vaccines for treatment and prevention

Cited by 17 publications

References 67 publications

Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer

Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer

Advances in MUC1-Mediated Breast Cancer Immunotherapy

Exploring chitosan-shelled nanobubbles to improve HER2 + immunotherapy via dendritic cell targeting

Contact Info

Product

Resources

About